Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

Lingling Du; Melissa DeFoe; Marianna B. Ruzinova; Jeffrey R. Olsen; Andrea Wang-Gillam

doi:10.1016/j.hoc.2015.04.011

Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

Lingling Du, Melissa DeFoe, Marianna B. Ruzinova, Jeffrey R. Olsen, Andrea Wang-Gillam

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.

Original language	English (US)
Pages (from-to)	717-726
Number of pages	10
Journal	Hematology/Oncology Clinics of North America
Volume	29
Issue number	4
DOIs	https://doi.org/10.1016/j.hoc.2015.04.011
State	Published - Aug 1 2015
Externally published	Yes

Keywords

Adjuvant therapy
HENT1
Neoadjuvant therapy
Predictive biomarkers
Resectable pancreatic cancer

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2015.04.011

Cite this

@article{20be330f3e5f4f4cab258d30fc399572,

title = "Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma",

abstract = "It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.",

keywords = "Adjuvant therapy, HENT1, Neoadjuvant therapy, Predictive biomarkers, Resectable pancreatic cancer",

author = "Lingling Du and Melissa DeFoe and Ruzinova, {Marianna B.} and Olsen, {Jeffrey R.} and Andrea Wang-Gillam",

note = "Funding Information: This publication was supported by the Washington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the National Center for Advancing Translational Sciences . The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.hoc.2015.04.011",

language = "English (US)",

volume = "29",

pages = "717--726",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

AU - Du, Lingling

AU - DeFoe, Melissa

AU - Ruzinova, Marianna B.

AU - Olsen, Jeffrey R.

AU - Wang-Gillam, Andrea

N1 - Funding Information: This publication was supported by the Washington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the National Center for Advancing Translational Sciences . The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health. Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.

AB - It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.

KW - Adjuvant therapy

KW - HENT1

KW - Neoadjuvant therapy

KW - Predictive biomarkers

KW - Resectable pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84938201822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938201822&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2015.04.011

DO - 10.1016/j.hoc.2015.04.011

M3 - Review article

C2 - 26226906

AN - SCOPUS:84938201822

SN - 0889-8588

VL - 29

SP - 717

EP - 726

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 4

ER -

Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this